Ciraparantag acetate is primarily investigated for its role as a reversal agent for anticoagulant drugs, especially direct oral anticoagulants (DOACs) and heparins. It is designed to rapidly neutralize the effects of these blood thinners in emergency situations, such as life-threatening bleeding or the need for urgent surgery. Unlike existing reversal agents that are specific to certain anticoagulants, ciraparantag has a broad-spectrum mechanism, binding to multiple anticoagulant classes including factor Xa inhibitors, unfractionated heparin, and low-molecular-weight heparins. This makes it a promising candidate for use in acute care settings where rapid restoration of normal clotting function is critical. Its potential to be administered subcutaneously or intravenously enhances its utility in both hospital and pre-hospital environments. Research is ongoing to confirm its safety and efficacy in clinical practice.